drugset / Trial / NCT00789698

Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

NCT00789698

Phase 3 Completed 240 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long term among schizophrenic outpatients with chronic schizophrenia.

Timeline

Start
2008-12
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 40 mg
Subject Lurasidone Small molecule 160 mg
Comparator Quetiapine Small molecule 200 mg
Comparator Quetiapine Small molecule 800 mg

Indications